Key result
Beta-blockers reduced mortality in post-myocardial infarction patients during the pre-reperfusion era, but recent evidence suggests they do not provide a mortality benefit in the modern era.
Why the study?
Does heart rate-lowering therapy reduce mortality in post-myocardial infarction patients in the contemporary reperfusion era?
Does heart rate-lowering therapy reduce mortality in post-myocardial infarction patients in the contemporary reperfusion era?
Answers are grounded in this paper and cite their sources.
The mortality benefit of long-term beta-blocker therapy in post-MI patients observed in older trials may not translate to contemporary practice with routine early reperfusion and comprehensive secondary prevention.
This commentary refers to ‘Heart rate-lowering drugs and outcomes in hypertension and/or cardiovascular disease: a meta-analysis’, by E. Sanidas et al., https://doi.org/10.1093/eurheartj/ehaf291 and the discussion piece ‘Beta-blockers in post-myocardial infarction patients: refractive errors in reading the evidence’, by E. Sanidas et al., https://doi.org/10.1093/eurheartj/ehaf1053. We read with great interest the article by Sanidas et al.1 and commend the authors for their contribution. Their meta-analysis of 26 post-acute myocardial infarction (MI) randomized controlled trials revealed a significant association between heart rate reduction and decreased mortality. However, 20 of these trials evaluated beta-blockers (BBs), with the majority conducted in the pre-reperfusion era. Prior meta-analysis published in 1999, which predominantly included trials performed in the pre-reperfusion era, demonstrated reduction in mortality with long-term BB therapy in post-MI patients.2 Most of these trials were conducted before the routine implementation of early coronary reperfusion strategies: thrombolytics, percutaneous coronary intervention, coronary bypass, statins, and more potent antiplatelet drugs. Thus, the magnitude of benefit from long-term BB in earlier trials in post-MI care may not fully translate to contemporary practice, where comprehensive secondary prevention is standard.3 Supporting this, a more recent meta-analysis in 2014, which included more recent studies, demonstrated that while BBs were associated with reduced mortality in the pre-reperfusion era, they did not show mortality benefit in the reperfusion era.4
No takes yet. Share an insight, caveat, or question.
Gvozdeva et al. (2025) conducted a letter in post-myocardial infarction. Beta-blockers was evaluated on mortality. Beta-blockers reduced mortality in post-myocardial infarction patients during the pre-reperfusion era, but recent evidence suggests they do not provide a mortality benefit in the modern era.
Synapse has enriched 10 related papers. Consider them for comparative context: